Gene Editing
With the development of gene editing therapeutics over the past decade, the need to define and understand companion off-target effects has come to the forefront. Several ideas were proposed to identify off-target risks with ONE-seq recently emerging as the most promising platform. SeQure Dx was founded to integrate ONE-seq into a comprehensive diagnostic portfolio that can provide a full assessment and subsequent management of off-target risks to fulfill the promise of gene editing’s therapeutic potential.
Discovery of off-target editing and SeQure’s history
SeQure Dx develops and launches NoteSeQ for partner off-target evaluations
FDA published draft guidance “Human Gene Therapy Products Incorporating Human Genome Editing”
SeQure Dx founded to identify and manage off-target risks for biopharma
ONE-seq developed in Keith Joung’s MGH lab to identify off-target editing
First CRISPR-based gene editing human clinical trial starts
GUIDE-seq developed in Keith Joung’s Lab to identify off-target editing
Fu, Y. et. al. “High-frequency off-target mutagenesis induced by CRISPR-cas nucleases in human cells ” published in Nature
First CRISPR-based gene editing companies are founded